Post-Transplantation Diabetes Mellitus in Pediatric Patients

More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occur...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hormone research in paediatrics 2021-04, Vol.93 (9-10), p.510-518
Hauptverfasser: Grundman, Jody B., Wolfsdorf, Joseph I., Marks, Brynn E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 518
container_issue 9-10
container_start_page 510
container_title Hormone research in paediatrics
container_volume 93
creator Grundman, Jody B.
Wolfsdorf, Joseph I.
Marks, Brynn E.
description More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.
doi_str_mv 10.1159/000514988
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33789298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507729277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgihtzB-8iBS96qObHmh_gReaPCROLzHNJk1SiXVuT9OB_b0ZnT17yAu_zHo8vAKcIXiOUiRsIYYYWgvMDMEWUkhRzTA_HP-ITMPf-MzJIOBOIHYMJIYwLLPgU3OatD-nGycZ3tWyCDLZtknsrSxOMT15MXdvQ-8Q2SW60lcFZleRRmSb4E3BUydqb-b7OwPvjw2a5StevT8_Lu3WqCBUhXRitEONMG7jYXauzioqSKUmF4VprRVVGWckR4brCGJZMGFppHZ9MIJ6RGbgc9nau_e6ND8XWehVPk41pe1_gDDKGBWYs0quBKtd670xVdM5upfspECx2eRVjXtGe79f25dboUf6lE8HZAL6k-zBuBOP8xb_t1Vs-iKLTFfkFDK95ow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507729277</pqid></control><display><type>article</type><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</creator><creatorcontrib>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</creatorcontrib><description>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>DOI: 10.1159/000514988</identifier><identifier>PMID: 33789298</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Child ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - etiology ; Diabetes Mellitus - therapy ; Humans ; Immunosuppressive Agents - administration &amp; dosage ; Immunosuppressive Agents - adverse effects ; Mini Review Article ; Organ Transplantation ; Postoperative Complications - diagnosis ; Postoperative Complications - etiology ; Postoperative Complications - therapy</subject><ispartof>Hormone research in paediatrics, 2021-04, Vol.93 (9-10), p.510-518</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>2021 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</citedby><cites>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</cites><orcidid>0000-0002-0193-4193 ; 0000-0002-4849-9774</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33789298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grundman, Jody B.</creatorcontrib><creatorcontrib>Wolfsdorf, Joseph I.</creatorcontrib><creatorcontrib>Marks, Brynn E.</creatorcontrib><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><title>Hormone research in paediatrics</title><addtitle>Horm Res Paediatr</addtitle><description>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</description><subject>Child</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes Mellitus - therapy</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Mini Review Article</subject><subject>Organ Transplantation</subject><subject>Postoperative Complications - diagnosis</subject><subject>Postoperative Complications - etiology</subject><subject>Postoperative Complications - therapy</subject><issn>1663-2818</issn><issn>1663-2826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M9LwzAUB_AgihtzB-8iBS96qObHmh_gReaPCROLzHNJk1SiXVuT9OB_b0ZnT17yAu_zHo8vAKcIXiOUiRsIYYYWgvMDMEWUkhRzTA_HP-ITMPf-MzJIOBOIHYMJIYwLLPgU3OatD-nGycZ3tWyCDLZtknsrSxOMT15MXdvQ-8Q2SW60lcFZleRRmSb4E3BUydqb-b7OwPvjw2a5StevT8_Lu3WqCBUhXRitEONMG7jYXauzioqSKUmF4VprRVVGWckR4brCGJZMGFppHZ9MIJ6RGbgc9nau_e6ND8XWehVPk41pe1_gDDKGBWYs0quBKtd670xVdM5upfspECx2eRVjXtGe79f25dboUf6lE8HZAL6k-zBuBOP8xb_t1Vs-iKLTFfkFDK95ow</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Grundman, Jody B.</creator><creator>Wolfsdorf, Joseph I.</creator><creator>Marks, Brynn E.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0193-4193</orcidid><orcidid>https://orcid.org/0000-0002-4849-9774</orcidid></search><sort><creationdate>20210401</creationdate><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><author>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Child</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes Mellitus - therapy</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Mini Review Article</topic><topic>Organ Transplantation</topic><topic>Postoperative Complications - diagnosis</topic><topic>Postoperative Complications - etiology</topic><topic>Postoperative Complications - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grundman, Jody B.</creatorcontrib><creatorcontrib>Wolfsdorf, Joseph I.</creatorcontrib><creatorcontrib>Marks, Brynn E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research in paediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grundman, Jody B.</au><au>Wolfsdorf, Joseph I.</au><au>Marks, Brynn E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-Transplantation Diabetes Mellitus in Pediatric Patients</atitle><jtitle>Hormone research in paediatrics</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>93</volume><issue>9-10</issue><spage>510</spage><epage>518</epage><pages>510-518</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><abstract>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</abstract><cop>Basel, Switzerland</cop><pmid>33789298</pmid><doi>10.1159/000514988</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0193-4193</orcidid><orcidid>https://orcid.org/0000-0002-4849-9774</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-2818
ispartof Hormone research in paediatrics, 2021-04, Vol.93 (9-10), p.510-518
issn 1663-2818
1663-2826
language eng
recordid cdi_pubmed_primary_33789298
source MEDLINE; Karger Journals; Alma/SFX Local Collection
subjects Child
Diabetes Mellitus - diagnosis
Diabetes Mellitus - etiology
Diabetes Mellitus - therapy
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - adverse effects
Mini Review Article
Organ Transplantation
Postoperative Complications - diagnosis
Postoperative Complications - etiology
Postoperative Complications - therapy
title Post-Transplantation Diabetes Mellitus in Pediatric Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A18%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-Transplantation%20Diabetes%20Mellitus%20in%20Pediatric%20Patients&rft.jtitle=Hormone%20research%20in%20paediatrics&rft.au=Grundman,%20Jody%20B.&rft.date=2021-04-01&rft.volume=93&rft.issue=9-10&rft.spage=510&rft.epage=518&rft.pages=510-518&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000514988&rft_dat=%3Cproquest_pubme%3E2507729277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2507729277&rft_id=info:pmid/33789298&rfr_iscdi=true